Key result
Pharmacological management using thrombolytic therapy, beta blockers, and aspirin is firmly established for the treatment of acute myocardial infarction based on major clinical trials.
This review summarizes the evidence establishing thrombolytic therapy, beta blockers, and aspirin as effective treatments for acute myocardial infarction.
Reinforces standard AMI pharmacological care; confirms major trial results in a Level 5 synthesis.
The routine medical management of patients with acute myocardial infarction (AMI) has undergone major changes in the last decade. Several large-scale trials have firmly established the effectiveness of thrombolytic therapy, beta blockers, and aspirin in the treatment of AMI. The critical issues include reducing myocardial oxygen demand and restoring adequate blood supply to the ischemic regions of the myocardium. As a result, the ability to intervene in patients with AMI has improved significantly. The purpose of this review is to discuss briefly the results of major trials of primary and secondary pharmacological intervention which had a direct impact on the care of patients with AMI. It concludes with current recommendations for the management of patients with AMI.
No takes yet. Share an insight, caveat, or question.
Jain et al. (1992) conducted a review in Acute myocardial infarction (AMI). Pharmacological management (thrombolytic therapy, beta blockers, aspirin) was evaluated. Pharmacological management using thrombolytic therapy, beta blockers, and aspirin is firmly established for the treatment of acute myocardial infarction based on major clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: